From Fragment Screening to In Vivo Efficacy: Optimization of a Series of 2-Aminoquinolines as Potent Inhibitors of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)

Yuan Cheng, Ted Judd, Michael D. Bartberger, +19

Journal of Medicinal Chemistry

STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells

Carol Babij, Yihong Zhang, Robert J. Kurzeja, +20

Cancer Research

Kras MutationsCancer ResearchStk33 KinaseStk33 Kinase ActivitySignal Transduction +12

Fragment-Linking Approach Using ¹⁹ F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β-Secretase

John B. Jordan, Douglas A. Whittington, Michael D. Bartberger, +4

Journal of Medicinal Chemistry

Concise Enantioselective Synthesis of (+)‐FR66979 and (+)‐FR900482: Dimethyldioxirane‐Mediated Construction of the Hydroxylamine Hemiketal

Ted Judd, Robert M. Williams

Angewandte Chemie International Edition

Bioorganic ChemistryUnique Hydroxylamine HemiketalOrganic ChemistryChemistryHeterocycle Chemistry +17

Design and Preparation of a Potent Series of Hydroxyethylamine Containing β-Secretase Inhibitors That Demonstrate Robust Reduction of Central β-Amyloid

Matthew M. Weiss, Toni Williamson, Safura Babu‐Khan, +35

Journal of Medicinal Chemistry

Structure Determination of Mycolactone C via Total Synthesis

Ted Judd, Alexander Bischoff, Yoshito Kishi, +2

Organic Letters

Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors

Thomas A. Dineen, Matthew M. Weiss, Toni Williamson, +38

Journal of Medicinal Chemistry

PharmacotherapyChemical BiologyPharmaceutical ChemistryPre-clinical PharmacologyTranslational Pharmacology +17

An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities

Yuan Cheng, James Brown, Ted Judd, +23

ACS Medicinal Chemistry Letters

Neurochemical BiomarkersPharmacotherapySocial SciencesPre-clinical PharmacologyCerebral Vascular Regulation +19

Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer’s disease

Jian Jeffrey Chen, Qingyian Liu, Chester Yuan, +34

Bioorganic & Medicinal Chemistry Letters

Alzheimer's DiseaseMedicine2-Aminooxazoline 3-AzaxanthenesPharmacological AgentAlzheimer ’ +7

A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β-Secretase

Matthew R. Kaller, Scott S. Harried, Brian K. Albrecht, +34

ACS Medicinal Chemistry Letters

Inhibitor 16Molecular PharmacologyMedicinal ChemistryNeurodegenerative DiseasesAlzheimer's Disease +13